Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023
Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in 2023
Strong financial position; cash runway into Q4 2024
Henry Schein, Inc. (Nasdaq: HSIC) announced today that its subsidiary, eAssist Dental Solutions (eAssist), has acquired a majority interest in Unitas PPO Solutions (Unitas), a privately held service provider that works with dental practices to assess their commercial insurance participation, set competitive fee-for-service rates, and negotiate contracted reimbursement with commercial insurers (PPO plans). The addition of Unitas is the result of a long-standing strategic relationship with Henry Schein that was formed in 2014 and offers a variety of service plans tailored to the specific needs of a dental practice.
Headquartered in Mesa, AZ, Unitas was founded in 2010 by Mike Alder to help dental practices negotiate PPO rates and optimize PPO participation. Mr. Alder will continue to manage the Unitas business as Chief Executive Officer, along with the current Unitas management team. In 2021, Unitas had sales of approximately $5 million. This transaction is expected to be neutral to Henry Schein’s 2022 diluted earnings per share and to be accretive thereafter. The financial terms of the transaction were not disclosed.
https://finance.yahoo.com/news/henry-schein-acquires-majority-interest-113000850.html
Walgreens Boots Alliance [s: wba] had a loss of $3.7 billion, or $4.31 per share, in the first quarter of 2023. It had a profit of $3.6 billion, or $4.13, in the same quarter in 2022. Adjusted earnings per share were $1.16 per share, against a FactSet consensus of $1.14. The earnings loss was attributed, in part, to a $5.2 billion after-tax charge for opioid claims. The retailer reported sales of $33.4 billion for the quarter, compared with $33.9 billion in the first three months of last year. The FactSet consensus was $32.9 billion. The company cited a 3% drop in sales in its U.S. Retail Pharmacy Business. Its U.S. healthcare business, which provides medical services and is a key part of the company's strategy going forward, reported sales of $989 million for the quarter. Walgreens reiterated EPS guidance of $4.45 to $4.65 for the year and adjusted sales guidance to $133.5 billion to $137.5 billion for 2023. The company's stock is down 30.6% over the past 12 months, while the broader S&P 500 [s: spx] has declined 19.6%.
Company expects to end 2022 with over $120M in cash, cash equivalents, and short-term investments and at the top of its net product revenue guidance of $105M-$110M
Company to report Q4 and FY 2022 financial results on or about March 8, 2023
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that, in connection with investor meetings the Company is planning to conduct next week in San Francisco, it has updated its outlook for full year 2022 expecting net product revenue to be at the top of its guidance range of $105 million to $110 million and its year-end cash balance to be above the previously announced range of $110 million to $120 million.
"Our momentum continued through the fourth quarter with strong patient demand for both Recorlev® and Keveyis® and better than expected prescription growth for Gvoke® giving us confidence that we will end 2022 at the top of our net product revenue guidance of $105 million to $110 million," said Paul R. Edick, Xeris’ Chairman and CEO. "Also in the fourth quarter, we drew down the final $50 million tranche from our Hayfin debt facility, received an upfront payment from the Horizon Therapeutics collaboration and option agreement, and continued disciplined management of our cash and expenses and expect to end 2022 with over $120 million in cash, cash equivalents, and short-term investments."
https://finance.yahoo.com/news/xeris-biopharma-updates-outlook-2022-120000703.html
FDA accepts nirsevimab application as first protective option against RSV disease for all infants
